search
Back to results

Safety and Effectiveness of Gamma Capsulotomy in Intractable OCD

Primary Purpose

Obsessive Compulsive Disorder

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Gamma Ventral Capsulotomy
Sponsored by
Butler Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Obsessive Compulsive Disorder

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. OCD, diagnosed by Structured Clinical Interview for DSM-IV (SCID-IV), judged of disabling severity with a Yale-Brown Obsessive Compulsive Scale (YBOCS) score of at least 30 and a Social and Occupational Functioning Assessment Scale (SOFAS) score of 45 or less.
  2. Persistence of severe symptoms and impairment for five or more years despite: 1. at least three adequate (≥3 months at the maximum tolerated dose) serotonin transporter inhibitor trials (fluoxetine, sertraline, fluvoxamine, paroxetine, citalopram, escitalopram, or clomipramine) alone or in combination with, 2. adequate behavior therapy (≥20 sessions of expert exposure and response prevention), and 3. augmentation of one of the selective SRIs with clomipramine, a neuroleptic, and clonazepam.
  3. Age between 18 and 65 years.
  4. Able to understand and comply with instructions.
  5. Able to give fully informed, written consent in the judgment of the Consent Monitor.
  6. Either drug free or on a stable drug regimen for at least 6 weeks.
  7. Good general health.
  8. A family member or significant other is available and willing to communicate with the research team if the patient's clinical status worsens.
  9. The local referring psychiatrist is willing to provide ongoing care.

Exclusion Criteria:

  1. Current or past psychotic disorder.
  2. Full-scale IQ below 85.
  3. A clinical history of bipolar mood disorder.
  4. Any current clinically significant neurological disorder or medical illness affecting brain function, other than tic disorders or Tourette syndrome.
  5. Any clinically significant abnormality on preoperative magnetic resonance imaging (MRI).
  6. Inability to undergo presurgical MRI (cardiac pacemaker, pregnancy, metal in body, severe claustrophobia.
  7. Current or unstably remitted substance abuse, dependence, or a positive urine toxicology screen.
  8. Pregnancy and women of childbearing age not using effective contraception.
  9. Unable to adhere to operational and administrative study requirements (in the investigators' judgment).
  10. Clinical history of severe personality disorder.
  11. Imminent risk of suicide (in the investigators' judgment).

Sites / Locations

  • Butler Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Gamma Ventral Capsulotomy

Arm Description

Outcomes

Primary Outcome Measures

Yale-Brown Obsessive Compulsive Severity Scale

Secondary Outcome Measures

Full Information

First Posted
February 12, 2013
Last Updated
August 9, 2017
Sponsor
Butler Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT01849809
Brief Title
Safety and Effectiveness of Gamma Capsulotomy in Intractable OCD
Official Title
Safety and Effectiveness of Gamma Capsulotomy in Intractable Obsessive Compulsive Disorder
Study Type
Interventional

2. Study Status

Record Verification Date
August 2017
Overall Recruitment Status
Completed
Study Start Date
February 1993 (undefined)
Primary Completion Date
August 2011 (Actual)
Study Completion Date
August 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Butler Hospital

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
A research study of the effectiveness and safety of gamma knife ventral capsulotomy in patients with severe intractable obsessive-compulsive disorder (OCD).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obsessive Compulsive Disorder

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Masking Description
Open Label
Allocation
N/A
Enrollment
57 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Gamma Ventral Capsulotomy
Arm Type
Experimental
Intervention Type
Procedure
Intervention Name(s)
Gamma Ventral Capsulotomy
Primary Outcome Measure Information:
Title
Yale-Brown Obsessive Compulsive Severity Scale
Time Frame
Baseline to 5 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: OCD, diagnosed by Structured Clinical Interview for DSM-IV (SCID-IV), judged of disabling severity with a Yale-Brown Obsessive Compulsive Scale (YBOCS) score of at least 30 and a Social and Occupational Functioning Assessment Scale (SOFAS) score of 45 or less. Persistence of severe symptoms and impairment for five or more years despite: 1. at least three adequate (≥3 months at the maximum tolerated dose) serotonin transporter inhibitor trials (fluoxetine, sertraline, fluvoxamine, paroxetine, citalopram, escitalopram, or clomipramine) alone or in combination with, 2. adequate behavior therapy (≥20 sessions of expert exposure and response prevention), and 3. augmentation of one of the selective SRIs with clomipramine, a neuroleptic, and clonazepam. Age between 18 and 65 years. Able to understand and comply with instructions. Able to give fully informed, written consent in the judgment of the Consent Monitor. Either drug free or on a stable drug regimen for at least 6 weeks. Good general health. A family member or significant other is available and willing to communicate with the research team if the patient's clinical status worsens. The local referring psychiatrist is willing to provide ongoing care. Exclusion Criteria: Current or past psychotic disorder. Full-scale IQ below 85. A clinical history of bipolar mood disorder. Any current clinically significant neurological disorder or medical illness affecting brain function, other than tic disorders or Tourette syndrome. Any clinically significant abnormality on preoperative magnetic resonance imaging (MRI). Inability to undergo presurgical MRI (cardiac pacemaker, pregnancy, metal in body, severe claustrophobia. Current or unstably remitted substance abuse, dependence, or a positive urine toxicology screen. Pregnancy and women of childbearing age not using effective contraception. Unable to adhere to operational and administrative study requirements (in the investigators' judgment). Clinical history of severe personality disorder. Imminent risk of suicide (in the investigators' judgment).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Steven Rasmussen, MD
Organizational Affiliation
Butler Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Butler Hospital
City
Providence
State/Province
Rhode Island
ZIP/Postal Code
02906
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
29361268
Citation
Rasmussen SA, Noren G, Greenberg BD, Marsland R, McLaughlin NC, Malloy PJ, Salloway SP, Strong DR, Eisen JL, Jenike MA, Rauch SL, Baer L, Lindquist C. Gamma Ventral Capsulotomy in Intractable Obsessive-Compulsive Disorder. Biol Psychiatry. 2018 Sep 1;84(5):355-364. doi: 10.1016/j.biopsych.2017.11.034. Epub 2017 Dec 15.
Results Reference
derived

Learn more about this trial

Safety and Effectiveness of Gamma Capsulotomy in Intractable OCD

We'll reach out to this number within 24 hrs